Teacher Retirement System of Texas Acquires 3,942 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Teacher Retirement System of Texas grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 44.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,860 shares of the company’s stock after purchasing an additional 3,942 shares during the quarter. Teacher Retirement System of Texas’ holdings in Vera Therapeutics were worth $544,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in VERA. AlphaQuest LLC bought a new position in Vera Therapeutics during the fourth quarter valued at $34,000. E Fund Management Co. Ltd. increased its holdings in Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after acquiring an additional 1,130 shares during the last quarter. KBC Group NV increased its holdings in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares during the last quarter. Arizona State Retirement System raised its stake in Vera Therapeutics by 22.9% in the 4th quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock valued at $532,000 after acquiring an additional 2,348 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Vera Therapeutics by 27.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $568,000 after purchasing an additional 2,882 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on VERA. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group began coverage on Vera Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price target for the company. Guggenheim lifted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $64.67.

Insider Activity

In related news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares in the company, valued at $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $24.02 on Tuesday. The stock has a market cap of $1.53 billion, a P/E ratio of -9.20 and a beta of 1.17. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The business’s 50-day moving average price is $30.74 and its two-hundred day moving average price is $38.80. Vera Therapeutics, Inc. has a twelve month low of $22.34 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.